International Journal of Pediatrics American-British classiﬁcation, frequency of myeloid antigen expression, and karyotypic abnormalities in 210 pediatric and adult cases,” American Journal of Clinical Pathology, vol. 111, no. 4, pp. 467–476, 1999. [22] M. F. Greaves, S. M. Colman, M. E. J. Beard, et al., “Geograph- ical distribution of acute lymphoblastic leukaemia subtypes: second report of the collaborative group study,” Leukemia, vol. 7, no. 1, pp. 27–34, 1993. [23] C.-H. Pui, F. G. Behm, B. Singh, et al., “Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia,” Blood, vol. 75, no. 1, pp. 174–179, 1990. [24] Z. Kaleem, E. Crawford, M. H. Pathan, et al., “Flow cytometric analysis of acute leukemias: diagnostic utility and critical anal- ysis of data,” Archives of Pathology and Laboratory Medicine, vol. 127, no. 1, pp. 42–48, 2003. [25] L. C. Brown and H. H. M. Knox-Macaulay, “Analysis of the immunophenotypes of de novo acute lymphoblastic leukaemia (ALL) in the Sultanate of Oman,” Leukemia Research, vol. 27, no. 7, pp. 649–654, 2003. [26] R. Paredes-Aguilera, L. Romero-Guzman, N. Lopez-Santiago, L. Burbano-Ceron, O. Camacho-Del Monte, and S. Nieto- Martinez, “Flow cytometric analysis of cell-surface and intra- cellular antigens in the diagnosis of acute leukemia,” American Journal of Hematology, vol. 68, no. 2, pp. 69–74, 2001. [27] A. Orfao, F. Ortun˜o, M. de Santiago, A. Lopez, and J. San Miguel, “Immunophenotyping of acute leukemias and myelodysplastic syndromes,” Cytometry A, vol. 58, no. 1, pp. 62–71, 2004. [28] I. M. Hann, S. M. Richards, O. B. Eden, and F. G. H. Hill, “Analysis of the immunophenotype of children treated on the Medical Research Council United Kingdom Acute Lym- phoblastic Leukaemia trial XI (MRC UKALLXI),” Leukemia, vol. 12, no. 8, pp. 1249–1255, 1998. [29] M. J. Borowitz, J. Shuster, A. J. Carroll, et al., “Prognostic signiﬁcance of ﬂuorescence intensity of surface marker expres- sion in childhood B-precursor acute lymphoblastic leukemia. A Pediatric Oncology Group study,” Blood, vol. 89, no. 11, pp. 3960–3966, 1997. [30] R. Consolini, A. Legitimo, R. Rondelli, et al., “Clinical rele- vance of CD10 expression in childhood ALL. The Italian Asso- ciation for Pediatric Hematology and Oncology (AIEOP),” Haematologica, vol. 83, no. 11, pp. 967–973, 1998. [31] F. M. Uckun, M. G. Sensel, L. Sun, et al., “Biology and treat- ment of childhood T-lineage acute lymphoblastic leukemia,” Blood, vol. 91, no. 3, pp. 735–746, 1998. [32] D. Campana and C.-H. Pui, “Detection of minimal residual disease in acute leukemia: methodologic advances and clinical signiﬁcance,” Blood, vol. 85, no. 6, pp. 1416–1434, 1995. [33] C.-H. Pui, S. C. Raimondi, D. R. Head, et al., “Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse,” Blood, vol. 78, no. 5, pp. 1327–1337, 1991. 7